#1 Clinical Trials Search in Europe

Datopotamab Deruxtecan

Datopotamab Deruxtecan (Dato-DXd) is an innovative antibody-drug conjugate being studied in clinical trials for various advanced cancers, particularly non-small cell lung cancer (NSCLC) and breast cancer. This article explores the ongoing research into Dato-DXd’s efficacy and safety as a potential treatment option for patients with limited alternatives.

Table of Contents

Introduction

Datopotamab deruxtecan is an innovative cancer treatment currently being studied in clinical trials. It’s a type of drug called an antibody-drug conjugate (ADC), which combines a targeted antibody with a potent chemotherapy drug[1]. This medication is also known by other names, including Dato-DXd and DS-1062a[2].

How Datopotamab Deruxtecan Works

Datopotamab deruxtecan works by targeting a specific protein called TROP2, which is found in high amounts on many cancer cells. The antibody part of the drug attaches to TROP2 on cancer cells. Then, the drug is taken into the cell where it releases a powerful chemotherapy agent. This targeted approach aims to kill cancer cells while minimizing damage to healthy cells[1].

Conditions Treated

Datopotamab deruxtecan is being studied for several types of cancer, including:

  • Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer. Datopotamab deruxtecan is being tested in patients with advanced or metastatic NSCLC, including those whose cancer has spread to the brain[1].
  • Breast cancer: Studies are looking at its effectiveness in different types of breast cancer, including HER2-negative and triple-negative breast cancers, especially when the cancer has spread to the brain[2].

Current Clinical Trials

Several clinical trials are currently underway to test datopotamab deruxtecan:

  • NSCLC with brain metastases: A phase II trial is studying how well the drug works in patients whose lung cancer has spread to the brain[1].
  • Breast cancer with brain metastases: Multiple studies are looking at its effectiveness in different types of breast cancer that have spread to the brain[2][4].
  • Combination therapy: A large phase III trial is comparing the combination of datopotamab deruxtecan with another drug called osimertinib to osimertinib alone in patients with certain types of NSCLC[5].

How It’s Administered

Datopotamab deruxtecan is given as an intravenous (IV) infusion, typically once every three weeks. The dose is usually calculated based on the patient’s body weight. For example, one common dosage is 6 mg/kg (6 milligrams for every kilogram of body weight)[1][2].

Potential Side Effects

As with any cancer treatment, datopotamab deruxtecan can cause side effects. While specific side effects are still being studied in clinical trials, some potential side effects may include:

  • Nausea and vomiting
  • Mouth sores (stomatitis)
  • Infusion-related reactions
  • Eye problems

Doctors often prescribe medications to help prevent or manage these side effects. It’s important to discuss potential side effects with your healthcare team[1].

Frequently Asked Questions

Is datopotamab deruxtecan approved for use?

As of now, datopotamab deruxtecan is not yet approved by the FDA. It’s still being studied in clinical trials to determine its safety and effectiveness[3].

How long can I receive datopotamab deruxtecan treatment?

In clinical trials, patients typically receive the treatment until their disease progresses, they experience unacceptable side effects, or they choose to discontinue. The exact duration can vary for each patient[1][2].

Can I participate in a clinical trial for datopotamab deruxtecan?

Eligibility for clinical trials depends on various factors, including your specific type of cancer, previous treatments, and overall health. Speak with your oncologist about whether you might be eligible for any ongoing trials[3].

Summary

AspectDetails
Drug TypeAntibody-drug conjugate (ADC)
TargetTROP2 protein on cancer cells
Conditions StudiedNSCLC, Breast Cancer (especially with brain metastases)
AdministrationIntravenous infusion, typically every 3 weeks
Current StatusIn clinical trials, not yet FDA approved

Glossary

  • Antibody-drug conjugate (ADC) – A type of cancer treatment that combines a targeted antibody with a chemotherapy drug
  • TROP2 – A protein found in high amounts on many cancer cells
  • Non-small cell lung cancer (NSCLC) – The most common type of lung cancer
  • Metastases – Areas where cancer has spread to other parts of the body
  • HER2-negative – A type of breast cancer that doesn’t have high levels of a protein called HER2
  • Triple-negative breast cancer – A type of breast cancer that doesn’t have receptors for estrogen, progesterone, or HER2

Trial Sources

  • [1]: https://clinicaltrials.gov/study/NCT06676917
  • [2]: https://clinicaltrials.gov/study/NCT06176261
  • [3]: https://clinicaltrials.gov/study/NCT06279728
  • [4]: https://clinicaltrials.gov/study/NCT05866432
  • [5]: https://clinicaltrials.gov/study/NCT06350097
Aspect Details
Drug Name Datopotamab Deruxtecan (Dato-DXd)
Drug Type Antibody-drug conjugate (ADC)
Target TROP2 protein on cancer cells
Main Cancer Types Studied Non-small cell lung cancer (NSCLC), Metastatic breast cancer (HER2-low, Triple-negative)
Key Clinical Trials TROPION-Lung08, TROPION-Lung10, DATO-BASE, TRADE DXd
Administration Intravenous infusion, typically 6 mg/kg every 3 weeks
Combination Therapies Pembrolizumab, Carboplatin, Rilvegostomig
Primary Outcomes Measured Objective Response Rate (ORR), Progression-Free Survival (PFS), Overall Survival (OS)
Special Populations Patients with brain metastases
Current Status Investigational; not yet FDA-approved for most indications

FAQ

  • What is Datopotamab Deruxtecan (Dato-DXd)? Datopotamab Deruxtecan is an antibody-drug conjugate consisting of a humanized anti-TROP2 monoclonal antibody linked to a topoisomerase I inhibitor payload. It works by targeting the TROP2 protein expressed on cancer cells, delivering the toxic payload directly to tumor cells.
  • What types of cancer is Dato-DXd being studied for? Dato-DXd is primarily being investigated for advanced non-small cell lung cancer (NSCLC) and metastatic breast cancer, including HER2-low and triple-negative subtypes. Some trials are specifically looking at its efficacy in patients with brain metastases.
  • How is Dato-DXd administered in clinical trials? In most trials, Dato-DXd is administered as an intravenous (IV) infusion, typically at a dose of 6 mg/kg body weight, given every 3 weeks (on Day 1 of each 21-day cycle).
  • What are some of the primary outcomes being measured in Dato-DXd trials? Key outcomes being assessed include objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and intracranial response rate for patients with brain metastases. Safety and tolerability are also important measures in these trials.
  • Is Dato-DXd being studied alone or in combination with other treatments? While some trials are investigating Dato-DXd as a monotherapy, others are exploring its potential in combination with other drugs such as pembrolizumab (an immunotherapy), carboplatin (chemotherapy), or novel agents like rilvegostomig.

Ongoing Clinical Trials on Datopotamab Deruxtecan

  • A study comparing datopotamab deruxtecan with durvalumab versus datopotamab deruxtecan alone for patients with PDL1-negative metastatic triple-negative breast cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Spain

  • A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Hungary Italy +2

  • Study comparing datopotamab deruxtecan with or without durvalumab to chemotherapy with pembrolizumab for patients with triple-negative breast cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Italy Poland Spain

  • A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +5

  • Study of Datopotamab Deruxtecan for Patients with Triple-Negative Breast Cancer and New or Worsening Brain Metastases

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Ireland

  • Study on the Safety and Effectiveness of Osimertinib and Datopotamab Deruxtecan for Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Italy Poland Spain

  • Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Hungary Ireland Italy Portugal +1

  • Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Germany Hungary Italy Poland +1

  • Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers

    Recruiting

    1 1 1
    Investigated drugs:
    Spain Sweden

Glossary

  • Antibody-drug conjugate (ADC): A type of targeted cancer therapy that combines a monoclonal antibody with a potent anti-cancer drug, designed to deliver the drug directly to cancer cells while minimizing damage to healthy cells.
  • TROP2: Trophoblast cell-surface antigen 2, a protein that is overexpressed in many types of cancer cells and serves as the target for Datopotamab Deruxtecan.
  • Non-small cell lung cancer (NSCLC): A type of lung cancer that accounts for about 80-85% of all lung cancers, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma subtypes.
  • HER2-low breast cancer: A subtype of breast cancer with low levels of HER2 protein expression, which falls between HER2-negative and HER2-positive classifications.
  • Triple-negative breast cancer: A type of breast cancer that tests negative for estrogen receptors, progesterone receptors, and excess HER2 protein, making it more challenging to treat with hormone therapies or HER2-targeted drugs.
  • Brain metastases: Cancer that has spread from its original site to the brain, often occurring in advanced stages of lung and breast cancers.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks (partial response) or disappears completely (complete response) after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standardized method for measuring tumor response in cancer clinical trials.
  • Pembrolizumab: An immunotherapy drug that works by helping the immune system detect and fight cancer cells.
  • Carboplatin: A chemotherapy drug commonly used to treat various types of cancers, including lung cancer.
  • Rilvegostomig: A novel investigational drug being studied in combination with Datopotamab Deruxtecan in some clinical trials.
  • Intracranial response: The response of brain metastases to treatment, often measured separately from overall response in patients with brain involvement.
  • Adverse events: Undesired harmful effects that occur during a clinical trial, used to assess the safety and tolerability of a treatment.